Disease-A-Month
Volume 53, Issue 5 , Pages 265-274 , May 2007

Autonomic Dysfunction in Parkinson’s Disease

References 

  1. Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson’s disease. Neurology. 2002;59:408–413
  2. Turkka JT, Myllyla VV. Sweating dysfunction in Parkinson’s disease. Eur Neurol. 1987;26:1–7
  3. Hirashima F, Yokota , Hayashi M. Sympathetic skin response in Parkinson’s disease. Acta Neurol Scand. 1996;93:127–132
  4. Finazzi-Agro E, Peppe A, D’Amico A, et al. Effects of subthalamic nucleus stimulation on urodynamic findings in patients with Parkinson’s disease. J Urol. 2003;169:1388–1391
  5. Jost WH, Eckardt VF. Constipation in idiopathic Parkinson’s disease. Scand J Gasterolenterol. 2003;7:681–686
  6. Allcock LM, Ullyart K, Kenny RA, et al. Frequency of orthostatic hypotension in a community based cohort of patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2004;75:1470–1471
  7. Turkka J, Suominen K, Tolonen U, et al. Selegiline diminishes cardiovascular autonomic responses in Parkinson’s disease. Neurology. 1997;48:662–667
  8. Goldstein DS. Dysautonomia in Parkinson’s disease: neurocardiological abnormalities. Lancet Neurol. 2003;2:669–676
  9. Goldstein DS, Pechnik S, Holmes C, et al. Association between supine hypertension and orthostatic hypotension in autonomic failure. Hypertension. 2003;42:136–142
  10. Lake CR, Ziegler MG, Kopin IJ. Use of plasma norepinephrine for evaluation of sympathetic neuronal function in man. Life Sci. 1976;18:1315–1325
  11. Bouhaddi M, Vuillier F, Fortrat JO, et al. Impaired Cardiovascular autonomic control in newly and long-term-treated patients with Parkinson’s disease: involvement of L-dopa therapy. Auton Neurosci. 2004;116:30–38
  12. Fowler CJ. Urinary disorders in Parkinson’s disease and multiple systems atrophy. Funct Neurol. 2001;16:277
  13. Araki I, Kitahara M, Oida T, et al. Voiding dysfunction and Parkinson’s disease: urodynamic abnormalities and urinary symptoms. J Urol. 2000;164:1640–1643
  14. Stocchi F, Carbone A, Inghilleri , et al. Urodynamic and neuropyschological evaluation in Parkinson’s disease and multiple systems atrophy. J Neurol Neurosurg Psychiatry. 1997;62:507–511
  15. Jankovic J, Tolossa E. In: Parkinson’s Disease and Movement Disorders. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002;
  16. Ashraf W, Pfeiffer RF, Park F, et al. Constipation in Parkinson’s disease: objective assessment and response to psyllium. Mov Disord. 1997;12:946–951
  17. Kuroiwa Y, Wada T, Tohgi H. Measurement of blood pressure and heart-rate variation while resting supine and standing for the evaluation of autonomic dysfunction. J Neurol. 1987;235:65–68
  18. Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the risk of Parkinson’s disease. Neurology. 2001;57:456–462
  19. Bassotti G, Maggio D, Battaglia E, et al. Manometric investigation of anorectal function in early and late stage Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2000;68:768–770
  20. Mathers SE, Kempster PA, Law PJ, et al. Anal sphincter dysfunction in Parkinson’s disease. Arch Neurol. 1989;46:1061–1064
  21. Den Hartog Jager WA. Sphingomyelin in Lewy inclusion bodies in Parkinson’d disease. Arch Neurol. 1969;21:615–619
  22. Forno LS. The Lewy body in Parkinson’s disease. Adv Neurol. 1986;45:35–43
  23. Kupsky WJ, Grimes MM, Sweeting J, et al. Parkinson’s disease and megacolon: concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology. 1987;37:1253–1255
  24. Ohama E, Ikuta F. Parkinson’s disease: distribution of Lewy bodies and monoamine neuron system. Acta Neuropathol. 1976;34:311–319
  25. Qualman SJ, Haupt HM, Yang P, et al. Esophageal Lewy bodies associated with ganglion cell loss in achalasia: similarity to Parkinson’s disease. Gastroenterology. 1984;87:848–856
  26. Wakabayashi K, Takahashi H, Ohame E, et al. Lewy bodies in the visceral autonomic nervous system in Parkinson’s disease. Adv Neurol. 1993;60:609–612
  27. Edwards L, Quigley EMM, Hoffman R, et al. Gastrointestinal symptoms in Parkinson’s disease: 18 month follow-up study. Mov Disord. 1993;8:83–86
  28. Wang SJ, Fuh JL, Liao KK, et al. Sympathetic skin response and R-R interval varation in Parkinson’s disease. Mov Disord. 1993;8:151–157
  29. Edwards LL, Pfeiffer RF, Quigley EMM, et al. Gastrointestinal symptoms in Parkinson’s disease. Mov Disord. 1991;6:151–156
  30. Soffer EE, Metcalf A, Launspach J, et al. Misoprostol is effective treatment for patients with severe constipation. Dig Dis Sci. 1994;39:929–933
  31. Roarty TP, Weber F, Soykan I, et al. Misoprostol in the treatment of chronic refractory constipation: results of a long-term open label trial. Aliment Pharmacol Ther. 1997;11:1059–1066
  32. Edwards LL, Quigley EM, Harned RK, et al. Defecatory function in Parkinson’s disease: response to apomorphine. Ann Neurol. 1993;33:490–493
  33. Eichhorn TE, Oertel WH. Macrogol 3550/electrolyte improves constipation in Parkinson’s disease and multi system atrophy. Mov Disord. 2001;16:1176–1177
  34. Wermuth C, Stenager E. Sexual problems in young patients with Parkinson’s disease. Acta Neurol Scand. 1995;91:453–455
  35. Hussain IF, Brady CM, Swinn MJ, et al. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson’s disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry. 2001;71:371–374
  36. Heaton J. Central neuropharmacological agents and mechanism in erectile dysfunction: the role of dopamine. Neurosci Behav Rev. 2000;24:561–569
  37. Raffaele R, Vecchio I. Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson’s disease. Eur Urol. 2002;41:382–386
  38. Dohanka M, Kanovsky P. Pergolide mesylate can improve sexual dysfunction in patients with Parkinson’s disease: the results of an open, prospective, 6-month follow-up. Eur J Neurol. 2004;483–488
  39. Mano Y, Nakamuro T, Takayanagi T, et al. Sweat function in Parkinson’s disease. J Neurol. 1994;241:573–576
  40. Sage JI, Mark MH. Drenching sweats as an off phenomenon in Parkinson’s disease: treatment and relation to plasma levodopa profile. Ann Neurol. 1995;37:120–122
  41. Bagheri H, Damase-Michel C, Lapeyre-Mestre M, et al. A study of salivary secreation in Parkinson’s disease. Clin Neuropharmacol. 1999;22:213–215
  42. Johnston BT, Li Q, Castell JA, et al. Swallowing and esophageal function in Parkinson’s disease. Am J Gastroenterol. 1995;90:1741–1746
  43. Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson’s disease. Neurology. 2004;62:37–40
  44. Mancini F, Zangaglia R, Cristina S, et al. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord. 2003;18:685–688

PII: S0011-5029(07)00007-7

doi: 10.1016/j.disamonth.2007.02.004

Disease-A-Month
Volume 53, Issue 5 , Pages 265-274 , May 2007

Article Tools